Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

45
A systematic review and meta-analysis of oncologic outcomes in localized resectable soft-tissue sarcoma Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC Malti Patel MD, FRCPC Michelle Ghert MD, FRCSC

description

A systematic review and meta-analysis of oncologic outcomes in localized resectable soft-tissue sarcoma. Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC Malti Patel MD, FRCPC Michelle Ghert MD, FRCSC. - PowerPoint PPT Presentation

Transcript of Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Page 1: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

A systematic review and meta-analysis of oncologic outcomes in localized

resectable soft-tissue sarcoma

Emad Al-Absi MDForough Farrokhyar PhD

Rajrish Sharma MDKaitlyn Whelan

Tom Corbett MD, FRCPCMalti Patel MD, FRCPC

Michelle Ghert MD, FRCSC

                                    

Page 2: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Background: Question Driven

If I have radiation first, won’t the tumor have a chance to spread?

Page 3: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Radiotherapy decreases local recurrence (1) Leibel SA, Tranbaugh RF, Wara WM, Beckstead JH, Bovill EG, Phillips TL. Soft tissue sarcomas of the extremities: survival and patterns of failure with conservative surgery and postoperative irradiation compared to surgery alone. Cancer 1982; 50(6):1076-1083.

• (2) Lindberg RD, Martin RG, Romsdahl MM, Barkley HT, Jr. Conservative surgery and postoperative radiotherapy in 300 adults with soft-tissue sarcomas. Cancer 1981; 47(10):2391-2397.

• (3) Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian SL et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998; 16(1):197-203.

• (4) Strander H, Turesson I, Cavallin-Stahl E. A systematic overview of radiation therapy effects in soft tissue sarcomas. Acta Oncol 2003; 42(5-6):516-531.

• (5) DeLaney TF. Optimizing radiation therapy and post-treatment function in the management of extremity soft tissue sarcoma. Curr Treat Options Oncol 2004; 5(6):463-476.

• (6) Scoggins CR, Pollock RE. Extremity soft tissue sarcoma: evidence-based multidisciplinary management. J Surg Oncol 2005; 90(1):10-13.

• (7) Barker JL, Jr., Paulino AC, Feeney S, McCulloch T, Hoffman H. Locoregional treatment for adult soft tissue sarcomas of the head and neck: an institutional review. Cancer J 2003; 9(1):49-57.

• (8) Callister MD, Ballo MT, Pisters PW, Patel SR, Feig BW, Pollock RE et al. Epithelioid sarcoma: results of conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys 2001; 51(2):384-391.

• (9) Suit H, Spiro IJ. Soft tissue sarcomas: radiation as a therapeutic option. Ann Acad Med Singapore 1996; 25(6):855-861.

• (10) Tepper JE, Suit HD. The role of radiation therapy in the treatment of sarcoma of soft tissue. Cancer Invest 1985; 3(6):587-592.

• (11) Zlotecki RA, Katz TS, Morris CG, Lind DS, Hochwald SN. Adjuvant radiation therapy for resectable retroperitoneal soft tissue sarcoma: the University of Florida experience. Am J Clin Oncol 2005; 28(3):310-316.

Page 4: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Timing of peri-operative radiotherapy

• Single randomized controlled trial (RCT) of pre- vs. post-operative radiation

• O’Sullivan et al, Lancet 2002• Primary endpoint: wound complications

increased with pre-operative radiation• Update 2005: late radiation morbidity

increased with post-operative radiation

Page 5: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Survival

• Not defined as a primary a priori endpoint• Trend towards improved survival in pre-

operative radiotherapy• ASCO Proceedings 2004: no difference in

survival or local recurrence

Page 6: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Available data

• One landmark RCT, but oncologic outcomes were not a priori primary outcomes and power analysis not applied

• Can we use retrospective/observational data?

Page 7: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC
Page 8: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Benson et al, NEJM 2000

Page 9: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Benson et al, NEJM 2000

Page 10: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Concato et al, NEJM 2000

Page 11: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

‘We found little evidence that estimatesof treatment effects in observational studies reported after 1984 are either consistently larger than or qualitatively different from those obtained in randomized, controlled trials.’ (N Engl J Med 2000;342:1878-86.)

Page 12: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

‘The results of well-designed observationalstudies (with either a cohort or a case–controldesign) do not systematically overestimate the magnitude of the effects of treatment as compared with those in randomized, controlled trials on the same topic.’ (N Engl J Med 2000;342:1887-92.)

Page 13: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Conclusion

• Well-designed observational studies are appropriate for systematically performed meta-analyses

Page 14: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Purpose

To determine oncologic outcomes in pre- vs. postoperative radiation in localized

resectable soft-tissue sarcoma

Page 15: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Methods

Page 16: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Literature search

• MEDLINE, EMBASE, CancerLit and the Cochrane Database

• Text words and Medical Search Headings (MeSH terms): ‘soft-tissue’, ‘sarcoma’, ‘radiation’, ‘preoperative’ and ‘postoperative’.

• Varying combinations of the Boolean operators “AND,” “NOT,” and “OR”

• English

Page 17: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Inclusion and exclusion criteria• Inclusion:

– Compare outcomes pre- vs post-operative radiation– Oncologic outcomes reported in both groups

• Exclusion– Advanced or metastatic disease– Only outcomes related to wound complications

and/or radiation dosages– Review articles– Only one publication per cohort (duplicates

excluded)

Page 18: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Assessment of methodological quality

• Two independent reviewers• Detsky Quality Scale for Randomized Trials• Ottawa-Newcastle Quality Assessment Scale

for case-control and cohort studies• Level of agreement: intra class correlation

coefficient

Page 19: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC
Page 20: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC
Page 21: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Outcomes

• Local recurrence• Overall survival

Page 22: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Statistical Analysis

• Cochran’s Q statistic for variability across studies

• Pooled odds ratio with 95% CI for local recurrence

• Fixed and random effects methods

Page 23: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Results

Page 24: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Potentially relevant papers screened (n=1794)

Trial did not meet inclusion criteria n=10

1 review article1 no pre-operative arm

6 no oncologic outcomes2 cohorts included in

subsequent publications

Abstracts retrieved (n=92)

Full article reviewed for further evaluation

(n=15)

Papers used in meta-analysis (n=5)

Excluded solely based on abstract (n=77)

Literature review flow diagram

Page 25: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Study characteristics

• One RCT and 4 observational studies• Total 1098 patients

– 526 pre-operative radiation– 572 post-operative radiation

• Publication dates 1985-2005• high level of agreement between reviewers

(intra-class correlation coefficient 0.973; P=0.001) for study quality [all high])

Page 26: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Oncologic variablesKuklo

et al

Zagars et al Suit et al Cheng et al O-Sullivan et al

Tumor size >10 cm (%)

Pre-opPost-op

35.526

4221

4318

NANA

3533

Radiation dosage (mean Gy)

Pre-opPost-op

5163

5060

50-5264-66

4862

5066

Resection margin% positivePre-opPost-op

NANA

2412

NANA

4042

1715

Page 27: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Local recurrence

• 4 studies with available data• 916 patients• 134 local recurrences• Risk for local recurrence lower in pre-

operative radiation with fixed effects method• Hazard ratio of 0.61 (95% CI, 0.42-0.89) • Random effects: HR 0.67 (95% CI, 0.39-1.15)

Page 28: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Forest Plot: Fixed effects method

Citation EffectName Pre-op Post-op PValue Effect Lower Upper

Cheng Local Recurrence 7 / 48 6 / 64 .394 1.650 .517 5.272

Kuklo Local Recurrence 3 / 59 7 / 58 .177 .390 .096 1.590

SUIT Local Recurrence 6 / 60 13 / 110 .719 .829 .298 2.306

Zagars Local Recurrence 36 / 271 56 / 246 .005 .520 .328 .824

Fixed Combined (4) 52 / 438 82 / 478 .012 .614 .420 .898

0.1 0.2 0.5 1 2 5 10

Pre-op Post-op

Page 29: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Forest plot: Random effects method

Citation EffectName Pre-op Post-op PValue Effect Lower Upper

Cheng Local Recurrence 7 / 48 6 / 64 .394 1.650 .517 5.272

Kuklo Local Recurrence 3 / 59 7 / 58 .177 .390 .096 1.590

SUIT Local Recurrence 6 / 60 13 / 110 .719 .829 .298 2.306

Zagars Local Recurrence 36 / 271 56 / 246 .005 .520 .328 .824

Random Combined (4) 52 / 438 82 / 478 .146 .671 .392 1.149

0.1 0.2 0.5 1 2 5 10

Pre-op Post-op

Page 30: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Overall survival

• Lack of raw data for calculation of odds ratio• Pre-operative 5-year survival: 76% (range, 62-

88%) • Post-operative 5-year survival: 67% (range 41-

83%) • Unable to determine statistical significance

Page 31: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Study heterogeneity

• P-value for heterogeneity 0.259• I2 for differences across studies due to

treatment effect 25%• Moderate but acceptable heterogeneity

Page 32: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Funnel Plot

-3 -2 -1 0 1 2 3

0

1

2

Stan

dard

Err

or o

f Log

OR

Log Odds Ratio

Funnel Plot of Standard Error by Effect Size

Page 33: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Discussion

Page 34: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Hierarchy of Evidence

Page 35: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

O’Sullivan et el, ASCO 2004

• Actuarial data• Local control:

– Pre-operative radiation: 93%– Post-operative radiation: 92%

• Local control not a primary endpoint of RCT • Pre-hoc power analysis for wound

complications

Page 36: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Local recurrence

• Pooled data from 4 high quality observational studies

• Data suggests improved local control with pre-operative radiation

• However, random effects methods (preferred for heterogenous data) OR crossed 1.0 (0.39-1.15)

Page 37: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Oncologic variablesKuklo

et al

Zagars et al Suit et al Cheng et al O-Sullivan et al

Tumor size >10 cm (%)

Pre-opPost-op

35.526

4221

4318

NANA

3533

Radiation dosage (mean Gy)

Pre-opPost-op

5163

5060

50-5264-66

4862

5066

Resection margin% positivePre-opPost-op

NANA

2412

NANA

4042

1715

Page 38: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Local Recurrence

• Oncologic variables suggest pre-operative group at higher risk for local recurrence

• Therefore lower risk suggested in the current analysis might have some validity

Page 39: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Local recurrence

• Less ambiguity with respect to radiation field• Dissection of tumor away from fixed

structures (bone, vessel, nerve) facilitated by pre-operative radiation

• Higher oxygen tension in pre-operative tissue

Page 40: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Background: Question Driven

If I have radiation first, won’t the tumor have a chance to spread?

Page 41: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Survival

• Pre-operative 76% (range, 62-88%) • Post-operative 67% (range 41-83%) • Is this statistically significant?• All time-dependent data therefore pooling and

analysis not possible

Page 42: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

O’Sullivan et el, ASCO 2004

• Actuarial data• Overall survival:

– Pre-operative radiation : 73%– Post-operative radiation: 67%– Results very similar to observational data

• (76% vs 67%)• Data does not suggest that waiting for surgery

will result in death from metastases

Page 43: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Conclusions

* Large amount of published observational data* One RCT* Strict adherence to Evidence Based Medicine

principles allows pooling of data* Suggestion of improved local control with pre-

operative radiation* Patients not at risk of death from metastases if

given pre-operative radiation

Page 44: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

References1. O'Sullivan,B. et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 359, 2235-2241 (2002).2. Suit,H.D., Mankin,H.J., Wood,W.C. & Proppe,K.H. Preoperative, intraoperative, and postoperative radiation in the treatment of primary soft tissue sarcoma. Cancer. 55, 2659-2667 (1985).3. Cheng,E.Y., Dusenbery,K.E., Winters,M.R. & Thompson,R.C. Soft tissue sarcomas: preoperative versus postoperative radiotherapy. J. Surg. Oncol. 61, 90-99 (1996).4. Kuklo,T.R. et al. Preoperative versus postoperative radiation therapy for soft-tissue sarcomas. Am. J. Orthop. 34, 75-80 (2005).5. Zagars,G.K. et al. Preoperative vs. postoperative radiation therapy for soft tissue sarcoma: a retrospective comparative evaluation of disease outcome. Int. J. Radiat. Oncol. Biol. Phys. 56, 482-488 (2003).

Page 45: Emad Al-Absi MD Forough Farrokhyar PhD Rajrish Sharma MD Kaitlyn Whelan Tom Corbett MD, FRCPC

Thank-you